Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger and SCAN domain-containing protein 29 (ZSCAN29) is a transcription factor characterized by the presence of both a C2H2-type zinc finger motif and a SCAN domain. The zinc finger domain enables specific DNA binding, allowing ZSCAN29 and other family members to regulate gene expression by targeting cis-acting DNA elements[1][2]. The SCAN domain mediates protein-protein interactions, including homo- and heterodimerization with other transcription factors, affecting transcriptional activity[1][3]. ZSCAN29 and the wider ZSCAN family are increasingly studied for their roles in gene expression modulation and potential involvement in cancer progression, differentiation, proliferation, and apoptosis; however, direct functional studies or disease links for ZSCAN29 itself remain limited in the published literature[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger and SCAN domain-containing protein 29 (ZSCAN29).